GRAFT VS HOST DISEASE
Clinical trials for GRAFT VS HOST DISEASE explained in plain language.
Never miss a new study
Get alerted when new GRAFT VS HOST DISEASE trials appear
Sign up with your email to follow new studies for GRAFT VS HOST DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising new combo aims to prevent deadly transplant complication
Disease control CompletedThis study tested a new drug combination (pacritinib, sirolimus, and tacrolimus) to prevent graft-versus-host disease (GVHD) in 40 blood cancer patients receiving a stem cell transplant from a matched donor. GVHD is a serious condition where donor cells attack the patient's body.…
Matched conditions: GRAFT VS HOST DISEASE
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 17, 2026 02:06 UTC
-
New drug combo shows promise in preventing deadly transplant complication
Disease control CompletedThis study tested whether adding the drug abatacept to standard medications (calcineurin inhibitor and methotrexate) could better prevent severe acute graft-versus-host disease (aGVHD) after a stem cell transplant from an unrelated donor. 186 participants aged 6 and older were ra…
Matched conditions: GRAFT VS HOST DISEASE
Phase: PHASE2 • Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug combo shows promise for kids with transplant complication
Disease control CompletedThis study tested adding the drug ruxolitinib to standard steroid treatment for children aged 28 days to under 18 years who had moderate to severe chronic graft-versus-host disease (cGvHD) after a stem cell transplant. cGvHD is a condition where donor immune cells attack the chil…
Matched conditions: GRAFT VS HOST DISEASE
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Could less immunosuppression after liver transplant be safer?
Disease control CompletedThis study looked at whether giving liver transplant patients fewer immune-suppressing drugs could lower their risk of a serious complication called graft-versus-host disease (GVHD), where donor cells attack the recipient's body. About 100 adults who received a liver or combined …
Matched conditions: GRAFT VS HOST DISEASE
Sponsor: Methodist Health System • Aim: Disease control
Last updated May 11, 2026 20:42 UTC
-
New hope for stem cell transplant patients: drug targets stubborn GvHD
Disease control CompletedThis study tested a drug called pomalidomide in 34 adults with chronic graft-versus-host disease (GvHD), a condition where donor immune cells attack the recipient's body after a stem cell transplant. Participants had GvHD that did not improve with standard treatments. They took p…
Matched conditions: GRAFT VS HOST DISEASE
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
Can a lupus drug stop transplant complications?
Disease control CompletedThis early study tested the drug belimumab (Benlysta) in 10 adults who had a stem cell transplant for blood cancer. The goal was to see if it could safely prevent chronic graft-versus-host disease (GvHD), a serious long-term complication where donor cells attack the patient's bod…
Matched conditions: GRAFT VS HOST DISEASE
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Apr 26, 2026 20:00 UTC
-
New drug shows promise in preventing transplant complication
Prevention CompletedThis study tested whether the drug obinutuzumab can prevent chronic graft-versus-host disease (cGVHD), a serious complication after a stem cell transplant. 181 people who had a stem cell transplant received obinutuzumab or a placebo. The goal was to see if the drug could reduce t…
Matched conditions: GRAFT VS HOST DISEASE
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Prevention
Last updated May 17, 2026 02:06 UTC